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INTRODUCTION 
Acute pancreatitis (AP) has a mortality of around 3% (1). Its reported incidence is 
variable across countries (10–100/100,000 inhabitants), and in the USA, AP is a 
significant cause of acute hospitalization for gastrointestinal disorders (2). Drug-
induced AP (DIAP) is regarded as a rare and mild entity, yet, it is estimated to 
account for about 2–5% of AP episodes worldwide (3, 4). Since DIAP has no unique 
features, rechallenge with the offending drug would be the only way to provide the 
most robust evidence to confirm the etiology. However, giving back the drug only 
for understanding the etiology of index AP is ethically unacceptable. (3) Therefore, 
unsurprisingly DIAP often remains a speculative diagnosis. A more detailed 
introduction of DIAP can be found in Supplementary document 1 (SD1).  
We aimed to systematically search the medical literature, analyze the outcomes of all 
reported cases of DIAP, and compare them to a general cohort of AP. 
METHODS 
We comprehensively searched the literature for reported cases of proven DIAP and 
extracted detailed data of each case on both first episodes and rechallenges. We 
compared DIAP to the large cohort of AP cases collected by the Hungarian 
Pancreatic Study Group. Details of the methods are in SD1. 
RESULTS 
As a result of the comprehensive search and selection, we identified and analyzed 
1060 eligible cases in 856 reports (details of the articles can be found in SD2). 
 
Epidemiology and outcome parameters of the first episodes of DIAP 
In a large proportion of the cases, antineoplastic 179/1060(16.89%), antibiotic 
128/1060(12.08%), and anticonvulsant 103/1060(9.72%) drugs caused DIAP. A 
combination of drugs caused 78/1060(7.36%) of the DIAP episodes (Figure1A). In 
approximately half of all cases, drugs were given to manage the diseases of the 
gastrointestinal tract 214/1060(20.19%), 158/1060(14.91%) neurologic and 
155/1060(14.62%) hematologic conditions (Figure1B). The ten most common drugs 
resulting in AP are shown in Figure1C. The male ratio of patients affected by DIAP 
was 536/1054(50.85%) (Figure1D). Interestingly, slightly more than the fifth of the 
cases were reported in children (under 18 years of age) 228/1054(21.63%), and cases 
were seen at a younger age than in AP of other common etiologies. (Figure1E). DIAP 
was severe in 213/1060(20.09%), moderately severe in 118/1060(11.13%), and mild in 
729/1060(68.77%) of the cases if the first episodes were analyzed (Figure1F). DIAP 
had a mortality of 90/1033(8.71%) for all severities (Figure1G). There was a 
significant difference in the LOH between mild and moderately severe (7days(IQR:4-
11.5) vs. 16days(IQR:7-25),P<0.001), and between mild and severe DIAP 
(7days(IQR:4-11.5) vs. 18days (IQR:6.5-42),P<0.001). There was no difference in the 
LOH between moderately severe and severe DIAP (Figure1H). Out of all 1060 
patients in our analysis, we found information on rechallenge in 960. Epidemiology 
(indication, gender, and age) and outcome parameters (severity, mortality, and LOH) 
of the rechallenge episodes of DIAP can be found in Figure 2A-F. The association of 
the drug categories and primary conditions with the severity and mortality rates of 
DIAP can be found in SD1/Supplementary Table 1-2 (ST1-2). 
 The effect of dose on the outcome of DIAP after rechallenge 
In 147/241(70.00%) cases, there was no data available on the dose for rechallenge. 
Rechallenge was performed in 49/241(20.33%) with the same dose as given in the 
first DIAP episode. In 33/241(13.69%) cases, the dose was decreased, and in 
12/241(4.98%) cases, the dose was increased compared to the drug dose given in the 
first episode. If the same dose was given, which provoked the first episode, DIAP 
was severe in 2/41(4.88%) cases, moderate in 3/41(7.32%) cases, and mild in 36/41 
(87.80%) cases. If decreased doses were given, we found no moderately severe cases. 
Rechallenge caused 1/28(3.57%) severe case and 27/28(96.43%) mild cases of DIAP 
(Figure 2G).   
 
Analysis of DIAP vs. the general AP cohort 
The descriptive statistics of the general AP cohort is shown in SD1/SF1. Our data 
showed that severity and mortality were increased in all DIAP compared to cases 
with AP of other etiologies by 18.41% vs. 5.63%(p<0.001), and 7.30% vs. 
2.20%(p<0.001). DIAP had the second highest mortality rate of all etiologies (8.49%) 
(SD1/SF1). 
  
 DISCUSSION  
One of the most critical findings of our study is that in comparison to AP of other 
etiologies, reported cases of DIAP to have a more severe disease course. Most 
medications causing severe DIAP are given to treat significant preexisting 
pathologies and primary diseases such as cancers and autoimmune disorders. These 
patients will have a higher risk of organ failure. In some patients, organ failure is 
present at the introduction of the offending drug, before the DIAP event. We 
hypothesize that this accounts for the increased proportion of moderately severe and 
severe cases of AP in the DIAP cohort. A primary disease is comorbidity itself and 
often has other comorbidities. We believe that the more severe the primary disease 
was, the higher doses of the offending drugs were used, leading to more severe 
courses of the DIAP cases. The offending drugs likely cause the DIAP in a dose-
dependent way. In our recent meta-analysis, older age lead to a more severe disease 
course (5), and our recent cohort analysis proved that comorbidities are more critical 
in AP than age (6). These conclusions are in line with the findings of the present 
study and support our above-detailed hypothesis. Besides the negative effect of 
comorbidities on the outcome of pancreatitis, culprit drugs have direct toxic effects 
on acinar cells as well. For example, asparaginase was shown to cause cellular 
necrosis (7). Importantly, here we report for the first time that when rechallenge was 
done with a decreased dose of the offending drug, it resulted in less severe outcomes. 
The main strength and limitations of this study are in SD1. 
Here we conclude that reported cases of DIAP have worse outcomes than AP of 
other etiologies and seem to be dose-dependent. If rechallenge is necessary, we 
recommend that patients are closely monitored and receive reduced drug dose. 
Evidence-based guidelines on DIAP and rechallenge should be developed. 
  
Figure legends: 
 
Figure 1. Epidemiology and outcome parameters of the first episodes of drug-
induced acute pancreatitis (DIAP; 1060 cases). A: Culprit drugs reported, 
subgrouped according to their mechanism of action. B: Primary diseases, which were 
the reason for the drug intake, subgrouped according to the affected organ. C: The 
top 10 culprit drugs. D: Gender ratio of patients. E: Age distribution of patients. F: 
Rate of the severities of cases. G: Mortality. H: Length of hospitalization (LOH) in the 
three different severities. 
 
Figure 2. Characterization of rechallenge events (241 cases). A: Reason of rechallenge. 
B: Gender distribution of cases. C: Age distribution of cases. D: Severities of cases. E: 
Mortality. F: Length of hospitalization (LOH) in the three severities. (ns: no 
significant difference). G: Correlation of drug doses and severity of drug-induced 
acute pancreatitis in rechallange.  If drug dose was the same during a rechallenge, 
the rate of mild and moderately severe AP cases was 3.42 times more frequent 
compared to the cases where rechallenge was performed with decreased doses.  
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EPIDEMIOLOGY AND OUTCOME PARAMETERS OF DRUG INDUCED AP
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Mesalamine 28 2.64%
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DETAILED INTRODUCTION 
Drug-induced AP (DIAP) is regarded as a rare entity, yet, it is estimated to 
account for about 2–5% of AP episodes worldwide (1-5). However, estimates vary 
due to the challenging diagnosis and the difficulties of causality assessment (6-8). 
Since DIAP has no unique features, which would help in distinguishing a case of 
DIAP from other etiologies, a rechallenge with the offending drug resulting a relapse 
of DIAP still means the most reliable evidence in confirming the etiology (3, 9). In 
most cases, intentional rechallenge is considered unethical due to the potentially life-
threatening complications of AP; therefore, DIAP remains a speculative diagnosis of 
exclusion. 
The subject of past reviews is usually the categorization of the drugs based on their 
reported frequency of provoking DIAP (4, 10) and the analysis of the strength of the 
causal relationship between the drug intake and the AP episode (11-13). According to 
the literature, most cases of DIAP are mild, self-limited, dose-independent, with a 
rapid resolution upon discontinuation of the offending drug (14, 15). However, in 
our previous study on 5-ASA-induced DIAP, we found that DIAP might not be dose-
independent, and we saw more moderately severe cases than expected (16).  
DETAILED METHODS 
Systematic search 
We performed a systematic literature search according to PRISMA guideline (17). 
The review was registered on PROSPERO under the ID number CRD42017079196. 
The following PECO items were used: P=patients with AP; E=DIAP; C=AP caused 
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by other etiologies; and O=severity, mortality, length of hospitalization (LOH), 
imaging alterations, symptoms, and time to resolution of AP. The search was 
performed in May 2019 on PubMed, EMBASE, and Cochrane Library with the search 
terms “acute pancreatitis” AND drug and was limited to English-language and 
human studies (if applicable) regardless of the date of publication. Study selection 
was performed by two independent researchers parallel. Studies that contained 
pooled statistical data of DIAP were excluded because they did not provide relevant 
data for our analysis. 
Inclusion and exclusion criteria 
Records which contained relevant data on cases of DIAP were eligible for our study 
irrespective of study design (case reports included as well). Cases reported as DIAP 
in which alcoholic or gallstone or different obvious etiology could be suspected were 
not included. 
Risk of bias 
We developed an assessment tool for the reporting quality of the identified articles to 
exclude poorly reported cases, which would threaten data quality and the analysis.  
We identified three categories of reporting quality, based on the reported symptoms 
and signs of AP (abdominal pain, pancreatic enzyme elevation, imaging changes) 
and their causality with the offending drug.  
Strong evidence: The report contained data sufficient to re-evaluate the event as 
DIAP.  
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Moderate evidence: The report described the event as DIAP, but data only partially 
confirmed it (could not be re-evaluated as AP).  
Weak evidence: The report described the event as DIAP, but there was no detailed 
data for re-evaluation. 
In our analysis, we included in the statistical analysis only cases with strong evidence 
levels. 
Definition of AP 
We re-evaluated all events documented by the authors as AP. Each was considered 
as AP if they met the criteria detailed in the evidence-based guidelines for the 
management of AP (18, 19). 
To assess severity any organ failure reported by the authors was accepted, even if 
there was no supporting data. Persistent organ failure was defined that lasted longer 
than 48 hours or described as persistent by the original authors themselves, transient 
organ failure was defined that resolved within 48 hours, or described as transient by 
the authors. 
We accepted the pancreatic enzyme level elevation as higher than triple the upper 
limit of normal if i. the exact enzyme level and the upper limit of normal were 
described, and the enzyme level exceeded more than three times, ii. the precise extent 
of elevation compared to the upper limit of normal was provided and was more than 
threefold iii. the exact pancreatic enzyme levels were given without their references, 
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but they were higher than 300 U/L in the case of amylase and 180 U/L in the case of 
lipase. 
Rechallenge 
We considered the result of rechallenge positive if a trial with the suspected 
offending drug resulted in the increase of the pancreatic enzyme levels with or 
without abdominal pain, nausea, or vomiting. 
Severity of DIAP 
To determine the severity of DIAP, we performed an evaluation using the data 
provided by the authors. We screened each case for the description of local and 
systemic complications and organ failure. If the detailed clinical data were available, 
the severity of DIAP was determined by the modified Atlanta criteria, irrespective of 
the classification by the original authors. If the lack of clinical data did not allow us to 
determine the severity of DIAP, we used the severity grade reported by the authors. 
Primary disease and drug categorization 
The offending drugs were given to manage specific disorders. We defined these as 
the primary diseases.  
Acute pancreatitis cohort 
For the comparative statistical analysis of the DIAP cases to analyze them against AP 
of other etiologies, we used the detailed clinical data of the AP cohort of the 
Hungarian Pancreatic Study Group, as described in our previous studies (20-23). 
Interpretation of data 
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We used descriptive statistical tools to characterize the population: relative frequency 
and median and interquartile range (IQR) were calculated. To analyze the differences 
between the severity groups for the LOH and the time of enzyme level and 
symptoms normalized, we applied the Kruskal-Wallis test with the Mann-Whitney U 
test as post hoc test. Differences between drug and disease categories and differences 
for DIAP against other etiologies of AP were examined using χ2-test. We regarded a 
p-value of <0.05 statistically significant. The available-case analysis was used for 
missing data. Statistical analyses were performed using IBM – Statistical Package for 
the Social Sciences (SPSS) for Windows software version 25 (IBM Corporation, 
Armonk, NY). 
ADDITIONAL RESULTS 
Outcomes of DIAP compared to AP with other etiologies 
We compared the severity and mortality rates of DIAP to AP caused by the more 
common aetiologies like biliary diseases, idiopathic etiology, alcohol consumption, 
lipid metabolism disorder, post-ERCP status, and the combinations of these. The 
detailed descriptive statistics of the AP cohort are shown in Supplementary Figure 1. 
We found that DIAP showed the most severe episodes if only the first episodes were 
analyzed 213/1060 (20.09%), Supplementary Figure 1. If the severe cases of first and 
rechallenged events were pooled, the rate of severe cases was slightly, but not 
significantly lower, 227/1301 (18.41%). Significant differences were seen between the 
rate of severe and mortality rates of DIAP cases if the first episodes are compared to 
rechallenges, 20.09% vs. 8.09% (p<0.001) and 8.49% vs. 2.07% (p < 0.001). Severity 
and mortality were increased in all DIAP compared to cases with all other etiologies 
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18.41% vs. 5.63% (p < 0.001), and 7.30% vs. 2.20% (p < 0.001). DIAP had the second 
highest mortality rate of all etiologies (8.49%). Only AP of combined alcoholic and 
biliary etiology had a similarily high mortality rate (8.7%) (Supplementary Figure 1). 
 
Supplementary Figure 1. The general cohort of acute pancreatitis (AP), A: sex ratio, B: age 
distribution, C: severity of acute pancreatitis, D: mortality, E: length of hospital stay (LOH),  
n: number of cases F: Severity and mortality rates of drug-induced acute pancreatitis (DIAP) 
compared to the other etiologies of acute pancreatitis. (a: drug induced first episodes vs drug 
induced rechallenges, p < 0.001; b: all DIAP vs all AP of other etiologies, p < 0.001;  
***: p < 0.001; **: p < 0.01; *: p < 0.05). Further significant differences are marked with stars 
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for other etiology vs first episodes of drug induced AP (***: p < 0.001, **: p < 0.01, *: p < 0.05). 
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The association of the drug categories with the severity and mortality rates of 
DIAP 
Antiprotozoal drugs, corticosteroids and antiretrovirals were responsible for the 
most severe cases of DIAP in 12/26 (46.15%), 13/30 (43.33%), and 7/19 (36.84%) 
respectively. Corticosteroids, antiprotozoal drugs and antiretrovirals had the highest 
mortality rates 12/30 (40.00%), 8/26 (30.77%), and 5/19 (26.32%) respectively. 
Antiprotozoals 46.15% (p<0.01), corticosteroids 43.33% (p<0.01), antihypertensives 
29.51% (p<0.05) and antineoplastic 24.58% (p<0.001) had a higher chance of severe 
disease than patients taking other drugs. In contrast to this, patients taking anti-
inflammatory drugs for IBD 10.53% (p<0.5), antibiotics 7.03% (p<0.001), or other 
drugs than the orther specified ones 14.29% (p<0.05) had a lower chance of a severe 
episode than patients taking other drugs. Anticonvulsants had a significantly higher 
chance of moderately severe DIAP 24.27% (p < 0.001) than patients taking other 
drugs. Corticosteroids 40.00% (p<0.001), antiprotozoals 30.77% (p<0.01), 
antiretrovirals 26.32% (p<0.05), antihypertensives 21.31% (p<0.01) and patients on 
multiple medications 15.58% (p<0.05) had a higher chance of mortality than other 
drugs. On the opposite, patients on antibiotics have a smaller chance of mortality 
than patients taking other drugs 3.15% (p < 0.05). (Supplementary Table 1). 
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RANKING BASED ON SEVERITY (CLASS OF DRUGS) 
 
 Frequency 
Severity Mortality Gender Age        SEVERITY 
 
  
Severe Moderate Mild Yes No Male Female <18 18-30 30-50 50-70 70< 
  
antiprotozoals  
n 26 12 2 
7.69 
 
12 8 18 18 8 0 13 13 0 0  
  
  46.15% 
% 2.45 46.15** 7.69 46.15 30.77** 69.23 69.23 30.77 0.00 50.00 50.00 0.00 0.00 
   
corticosteroids  
n 30 13 3 14 12 18 18 12 11 4 6 8 1 
    
% 2.83 43.33** 10.00 46.67 40.00*** 60.00 60.00 40.00 36.67 13.30 20.00 26.67 3.33 
    
antiretrovirals (AIDS) 
n 19 7 3 9 5 14 11 8 3 3 10 3 0 
    
% 1.79 36.84 15.79 47.37 26.32* 73.68 57.89 42.11 15.79 15.79 52.63 15.79 0.00 
    
antipsychotics  
n 40 12 6 22 3 37 26 14 2 7 21 6 3 
    
% 3.77 30.00 15.00 55.00 7.50 92.50 65.00 35.00 5.13 17.95 53.85 15.38 7.69 
    
antihypertensives  
n 61 18 1 42 13 48 34 27 0 7 13 33 8 
    
% 5.75 29.51* 1.64 68.85 21.31** 78.69 55.74 44.26 0.00 11.48 21.31 54.10 13.11 
    
analgesics (non-NSAID) 
n 17 5 0 12 1 16 3 14 2 4 6 4 1 
    
% 1.60 29.41 0.00 70.59 5.88 94.12 17.65 82.35 11.76 23.53 35.29 23.53 5.88 
    
gonadal hormones 
n 25 7 3 15 1 24 8 17 0 8 16 1 0 
    
% 2.36 28.00 12.00 60.00 4.00 96.00 32.00 68.00 0.00 32.00 64.00 4.00 0.00 
    
anti-diabetics 
n 54 15 6 33 3 51 24 30 0 2 14 28 10 
    
% 5.09 27.78 11.11 61.11 5.56 94.44 44.44 55.56 0.00 3.70 25.93 51.85 18.52 
    
antineoplastics 
n 179 44 35 100 8 147 83 96 86 18 30 37 8 
    
% 16.89 24.58*** 19.55 55.87 5.16 94.84 46.37 53.63 48.04 10.06 16.76 20.67 4.47 
    
anticonvulsants 
n 103 19 25 59 9 94 61 39 62 15 12 7 5 
    
% 9.72 18.45*** 24.27 57.28 8.74 91.26 61.00 39.00 61.39 14.85 11.88 6.93 4.95 
    
immunosuppressants 
n 33 4 2 27 0 32 19 13 10 8 6 8 1 
    
% 3.11 12.12 6.06 81.82 0.00 100.00 59.38 40.63 30.30 24.24 18.18 24.24 3.03 
    
non-steroidal anti-inflammatory 
drugs (NSAID) 
n 37 4 1 32 0 37 15 22 6 5 7 10 9 
    
% 3.49 10.81 2.07 86.49 0.00 100.00 40.54 59.46 16.22 13.51 18.92 27.03 24.32 
    
anti-inflammatory drugs for IBD 
n 38 4 1 33 2 36 16 22 9 12 16 1 0 
    
% 3.58 10.53* 2.63 86.84 5.26 94.74 42.11 57.89 23.68 31.58 42.11 2.63 0.00 
    
antivirals (other than AIDS) 
n 29 3 2 24 1 28 17 12 1 3 12 11 2 
    
% 2.74 10.34 6.90 82.76 3.45 96.55 58.62 41.38 3.45 10.34 41.38 37.93 6.90 
    
lipid lowerings 
n 21 2 2 17 2 19 8 13 0 1 3 11 6 
    
% 1.98 9.52 9.52 80.95 9.52 90.48 38.10 61.90 0.00 4.78 14.29 52.38 28.57 
    
antibiotics  
n 128 9 9 110 4 123 58 69 12 28 34 30 22 
    
% 12.08 7.03*** 7.03 85.94 3.15* 96.85 45.67 54.33 9.52 22.22 26.98 23.81 17.46 
    
psychoactives 
n 16 1 2 13 1 15 15 1 1 10 4 0 1 
  6.25% 
% 1.51 6.25 12.50 81.25 6.25 93.75 93.75 6.25 6.25 62.50 25.00 0.00 6.25 
  
other 
n 126 18 8 100 5 121 61 64 18 14 37 36 20 
    
% 11.89 14.29* 6.35 79.37 3.97 96.03 48.80 51.20 14.40 11.20 29.60 28.80 16.00 
    
on multiple medications 
n 78 16 7 55 12 65 41 37 5 13 19 32 9 
    
% 7.36 20.51 8.97 70.51 15.58* 84.42 52.56 47.44 6.41 16.67 24.36 41.03 11.54 
    
TOTAL 
n 1060 213 118 729 90 943 536 518 228 175 279 266 106 
    
% 100.00 20.09 11.13 68.77 8.71 91.29 50.85 49.15 21.63 16.60 26.47 25.24 10.06 
    
Supplementary Table 1. The association of the drug categories with the severity and mortality rates of drug-induced acute pancreatitis (***: p < 0.001, **: p < 0.01, *: p < 0.05). 
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The association of the primary conditions with the severity and mortality rates of 
DIAP 
The severity of DIAP was analyzed for subgroups of primary diseases, which 
showed that patients with breast cancer, hematological conditions, and 
cardiovascular failure had the highest rates of severe DIAP, 6/19 (31.58%); 45/155 
(29.03%) and 20/77 (25.97%) respectively. Underlying gastrointestinal tract disease 
had a lower chance of severe DIAP 12.15% (p<0.001) than other diseases. 
Hematologic disorders had a higher rate of a severe DIAP episode 29.03% (p<0.001) 
than in other conditions. Neurologic conditions have a significantly higher chance for 
a moderately severe DIAP 20.89% (p<0.001), than in other diseases. Mortality was 
lower among patients with GI tract disease 3.38% (p<0.01), and higher in multiple 
diseases 19.61% (p<0.05), heart and circulatory diseases 19.48% (p<0.001) and 
systemic diseases 17.65% (p<0.05), than in other diseases (Supplementary Table 2). 
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RANKING BASED ON SEVERITY (ORGAN SYSTEMS AFFECTED BY THE PRIMARY DISEASES) 
 
 Frequency 
Severity Mortality Gender Age 
SEVERITY  
  
Severe Moderate Mild Yes No Male Female <18 18-30 30-50 50-70 70<  
breast cancer 
n 19 6 3 10 0 19 0 19 0 0 13 6 0 
 
 
 
 
31.58% 
% 1.79 31.58 15.79 52.63 0.00 100.00 0.00 100.00 0.00 0.00 68.42 31.58 0.00 
  
hematologic 
n 155 45 29 81 15 122 84 71 90 23 22 17 3 
   % 14.62 29.03*** 18.71 52.26 10.95 89.05 54.19 45.81 58.06 14.84 14.19 10.97 1.94 
   
heart and circulation 
n 77 20 3 54 15 62 39 38 1 9 14 38 15 
   % 7.26 25.97 3.90 70.13 19.48*** 80.52 50.65 49.35 1.30 11.69 18.18 49.35 19.48 
   
respiratory tract  
n 46 10 3 33 5 40 23 23 3 6 14 17 6 
   % 4.34 21.74 6.52 71.74 11.11 88.89 50.00 50.00 6.52 13.04 30.43 36.96 13.04 
   
systemic  
n 51 11 3 37 9 42 26 25 10 8 13 14 6 
   % 4.81 21.57 5.88 72.55 17.65* 82.35 50.98 49.02 19.61 15.69 25.49 27.45 11.76 
   
neurologic 
n 158 31 33 94 10 148 88 69 62 28 38 20 9 
   % 14.91 19.62*** 20.89 59.49 6.33 93.67 56.05 43.95 39.49 17.83 24.20 12.74 5.73 
   
bone, muscle, cartilage, skin 
n 66 11 9 46 3 62 35 30 11 5 12 20 16 
   % 6.23 16.67 13.64 69.70 4.62 95.38 53.85 46.15 17.19 7.81 18.75 31.25 25.00 
   
genitourinary system 
n 81 13 6 62 7 74 26 54 6 19 33 17 6 
   % 7.64 16.05 7.41 76.54 8.64 91.36 32.50 67.50 7.41 23.46 40.74 20.99 7.41 
   
gastrointestinal tract 
n 214 26 16 172 7 200 112 101 21 31 52 79 30 
   % 20.19 12.15*** 7.48 80.37 3.38** 96.62 52.58 47.42 9.86 14.55 24.41 37.09 14.08 
   
thyroid gland 
n 14 1 1 12 0 14 2 12 2 0 4 5 3 
  7.14% % 1.32 7.14 7.14 85.71 0.00 100.00 14.29 85.71 14.29 0.00 28.57 35.17 21.43 
 
other 
n 105 21 8 76 7 98 59 44 14 27 35 18 9 
   % 9.91 20.00 7.62 72.38 6.67 93.33 57.28 42.72 13.59 26.21 33.98 17.48 8.74 
   
multiple diseases 
n 51 16 4 31 10 41 31 20 7 14 21 7 2 
   % 4.81 31.37 7.84 60.78 19.61* 80.39 60.78 39.22 13.73 27.45 41.18 13.73 3.92 
   
no data 
n 23 2 0 21 2 21 11 12 1 5 8 8 1 
   % 2.17 8.70 0.00 91.30 8.70 91.30 47.83 52.17 4.35 21.74 34.78 34.78 4.35 
   
TOTAL 
n 1060 213 118 729 90 943 536 518 228 175 279 266 106 
   % 100 20.09 11.13 68.77 8.71 91.29 50.85 49.15 21.63 16.60 26.47 25.24 10.06 
    
Supplementary Table 2. The association of the primary conditions with the severity and mortality rates of drug-induced acute pancreatitis (***: p < 0.001, **: p < 0.01, *: p < 0.05).
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STRENGTHS 
To our knowledge, this is the only study which comprehensively searched and 
identified all DIAP cases in the literature.  
We followed a rigorous methodology, including data extraction and quality analysis 
of each individual article, to generate an extensive database of reported cases of 
DIAP. We used this broad database to analyze the natural history of DIAP. 
Our systematic and comprehensive search identified and resulted in a very detailed 
data of 1060 cases of DIAP. To date, this is the largest and most comprehensive 
analysis of all reported cases of DIAP. As we collected data on the first episodes of 
DIAP and on rechallenges, we could compare the two entities. 
LIMITATIONS  
This study is based on data extracted from case reports and case series, which 
introduces all of the limitations of the genre, most importantly recall and publication 
bias (24). The publication bias was increased by the English language filter, which we 
had to use due to a large number of records identified by the preliminary search. 
Case reports and series publications, which are almost always written in retrospect, 
may contain insufficient data, which is a concern.  
The latency period between drug exposure and the start of the pancreatitis episode 
was not defined, and this is a limitation of our study. Due to the lack of data, Naranjo 
score could not be used (25), which is another significant limitation of the 
interpretation of the results. 
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The definition of DIAP after rechallenge needs careful consideration. The fluctuation 
of pancreatic enzyme levels and incomplete resolution of morphological changes 
after an episode of acute pancreatitis make the clinical assessment of recurrent 
pancreatitis difficult, following the rechallenge with the suspected drug. 
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